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Abstract
Background: Of the five sub-phenotypes defining metabolic syndrome, all are known to have
strong genetic components (typically 50–80% of population variation). Studies defining genetic
predispositions have typically focused on older populations with metabolic syndrome and/or type
2 diabetes. We hypothesized that the study of younger populations would mitigate many
confounding variables, and allow us to better define genetic predisposition loci for metabolic
syndrome.
Methods: We studied 610 young adult volunteers (average age 24 yrs) for metabolic syndrome
markers, and volumetric MRI of upper arm muscle, bone, and fat pre- and post-unilateral resistance
training.
Results:  We found the PPARα L162V polymorphism to be a strong determinant of serum
triglyceride levels in young White males, where carriers of the V allele showed 78% increase in
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triglycerides relative to L homozygotes (LL = 116 ± 11 mg/dL, LV = 208 ± 30 mg/dL; p = 0.004).
Men with the V allele showed lower HDL (LL = 42 ± 1 mg/dL, LV = 34 ± 2 mg/dL; p = 0.001), but
women did not. Subcutaneous fat volume was higher in males carrying the V allele, however,
exercise training increased fat volume of the untrained arm in V carriers, while LL genotypes
significantly decreased in fat volume (LL = -1,707 ± 21 mm3, LV = 17,617 ± 58 mm3 ; p = 0.002),
indicating a systemic effect of the V allele on adiposity after unilateral training. Our study suggests
that the primary effect of PPARα L162V is on serum triglycerides, with downstream effects on
adiposity and response to training.
Conclusion: Our results on association of PPARα and triglycerides in males showed a much larger
effect of the V allele than previously reported in older and less healthy populations. Specifically, we
showed the V allele to increase triglycerides by 78% (p = 0.004), and this single polymorphism
accounted for 3.8% of all variation in serum triglycerides in males (p = 0.0037).
Background
Metabolic syndrome is considered to be a pre-diabetic
state, with abnormal values for triglycerides, HDL, adipos-
ity, blood pressure, and insulin resistance [1]. Twin and
family studies have demonstrated the prominent influ-
ence of genetic factors on metabolic syndrome sub-phe-
notypes [2,3]. To date, most research aimed to identify
these genetic underpinnings have been done in elderly or
diseased populations. Less progress has been made on the
identification of initial risk factors such as lipid levels and
insulin resistance in young individuals. With regards to
these sub-phenotypes, it is known that the genetic factors
in an aged population may be different than those in a
younger population. For example, a longitudinal twin
study has reported that only 40% of the genetic factors
affecting BMI are shared at the age of 20 y and 40 y [4].
We have previously described a genetic association study
of university-age young adults, with measurement of base-
line strength and tissue volumes of the upper arm, then
response to a 12 wk unilateral resistance training of the
non-dominant arm [5-8]. We chose the non-dominant
arm to minimize environmental influences (use), and
thus maximize sensitivity for detecting genetic influences.
We recently expanded the study to include baseline meta-
bolic syndrome measures. In this study, we used upper
arm subcutaneous fat as a surrogate marker for adiposity,
although visceral fat is more highly studied as a measure
of obesity. Here, our goal was to test the effect of the
PPARα gene polymorphism (L162V) on a young adult
volunteer population, and to begin to better dissect the
effects of PPARα genotype on the earliest phenotypes.
Peroxisome-proliferator-receptor-alpha (PPARα) is
involved in adipocyte differentiation, lipid and lipopro-
tein metabolism. Studies in mice have shown that PPARα-
deficient animals were unable to metabolize lipids and
develop late onset obesity even when kept on a stable diet
[9,10]. PPARα is activated by circulating fatty acids, and
peroxisome proliferator receptor agonists such as hypoli-
pidemic drugs (fibrates), commercially used plasticizers,
synthetic fatty acids, steroid hormones, herbicides and
pesticides [11]. Activation of the receptor results in the
increased expression of genes involved in lipid oxidation,
lipoprotein metabolism, inhibition of vascular inflamma-
tion and adipocyte differentiation through binding to per-
oxisome proliferator response elements (PPRE) in the
DNA sequence of target genes [12]. In summary the acti-
vation of PPARα stimulates fatty acid transportation and
oxidation primarily in liver and muscle reducing the stor-
age of fat in adipocytes. Thus, PPARα is a strong candidate
gene for the genetic component of metabolic syndrome.
The PPARα gene has been screened for common polymor-
phic variations. The most studied variant is a missense
mutation in exon 5 that results in a nonconservative
amino acid substitution, leucine 162 valine (L162V). The
V allele is Leucine 162 is located within the DNA binding
domain and is highly conserved among species [13,14].
Functional studies of the PPARα L162V polymorphism
have shown differences in the activity of the receptor
depending on the ligand concentration. At low ligand
concentrations the activity of the receptor was lower for
the V isoform than the L isoform, whereas at high ligand
concentrations the opposite occurred (V activity decreased
relative to L) [15]. The L162V polymorphism has been
previously associated with dyslipidemia [16-21], and
some measures of adiposity [22,23]. However, some of
these studies showed opposite findings or negative associ-
ations. Many factors may contribute to an inability to rep-
licate genetic association studies. First, differences in the
population studied with most published studies focusing
on older or unhealthy populations. Second, different
methods of measuring both regional and total adiposity
are used, and each of these methods has well-documented
issues concerning reliability of measure, sensitivity, and
specificity for measuring fat.
The aim of this study was to identify the role that PPARα
L162V polymorphism may play in the variability of serumBMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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lipid concentration and variations in subcutaneous fat
volume and BMI in 610 young healthy volunteers (aver-
age age 24 years). Fat volume was determined using semi-
automated three-dimensional reconstruction analysis
software. We tested the PPARα L162V polymorphism
against our volumetric MRI measures and variations in
serum lipid profiles. We found strong statistical support
for sex-specific effects of PPARα genotype with plasma
triglyceride, HDL, and BMI. The effect of PPARα genotype
was much stronger in our young adult population than
previously reported for older populations, suggesting that
younger populations may afford greater sensitivity in
identification of the genetic underpinnings of metabolic
syndrome sub-phenotypes.
Methods
Study overview and subjects
The study population was derived from a multicenter,
NIH funded study designed to identify genetic factors that
dictate baseline bone, muscle and fat volume and the var-
iability in response to exercise training. The study design
protocol has been described in detail elsewhere [24], and
preliminary reports of genetic associations with muscle
strength and size have been reported [5-8]. Briefly, 1,300
men and women, average age 24 (range 18 – 40 yrs) were
recruited by one of the 8 centers (University of Massachu-
setts Amherst, University of Connecticut, Dublin Univer-
sity (Ireland), Florida Atlantic University, Hartford
Hospital, University of Central Florida, West Virginia Uni-
versity, Central Michigan University). Participants were
excluded if they: were <18 y or >40 y; used medications
known to affect skeletal muscle such as corticosteroids;
had any restriction of activity; had chronic medical condi-
tions such as diabetes; had metal implants in arms, eyes,
head, brain, neck, or heart which would prohibit MRI test-
ing; had performed strength training or employment
requiring repetitive use of the arms within the prior 12
months; consumed on average >2 alcoholic drinks daily;
or had used dietary supplements reported to build muscle
size/strength or to cause weight gain such as protein sup-
plements, creatine, or androgenic precursors. Subjects
were asked to maintain their normal dietary intake for the
duration of the study. Written informed consent was
obtained from each volunteer. The study was approved by
the Children's National medical Center Institutional
Review Board (protocol #2449), and was in compliance
with the Helsinki Declaration.
We limited this current study to 610 Caucasians that had
values for entry metabolic syndrome markers, completed
pre- and post-MRI measurements, or both (table 1).
Exercise Training Program
Resistant training was performed with the non-dominant
arm. The protocol was described elsewhere [24]. Briefly it
consisted of two 45 – 60 minute sessions per week for 12
weeks. Each session was supervised by an exercise physiol-
ogist professional or a trained student. Before each ses-
sion, participants warmed-up with 2 sets of 12 repetitions
of the biceps preacher curl and the seated overhead triceps
extension. Each session included dumbbell biceps curls,
dumbbell biceps preacher curls, and incline dumbbell
biceps curls, overhead dumbbell triceps extension, and
dumbbell triceps kickbacks. The amount of weight was
aggressively increased during the 12 wks.
Subject Phenotyping
Anthropometric assessment
Body weight was recorded before and after the exercise
training using a balance beam scale. Height was measured
using a tape mounted on a wall and recorded in inches.
BMI was calculated from weight (kg) and height (m).
MRI assessment
Subjects were scanned in the supine position with arms at
their sides and their palms up on the scanner bed surface.
The arm maximum circumference was determined with
the subject standing, with the shoulder abducted at 90
degrees, the hand supinated, and the biceps flexed. A vita-
min E bead was placed on the front of the biceps portion
of the arm with the largest circumference to standardized
MRI measurements by comparing the bead's measured
cross sectional area with that of the MRI determined cross
sectional area.
Entry MRI was done 24 to 48 h before the isometric or
1RM (1 repetition maximum) test. Scans post-training
MRI was performed 48 – 96 h after the last training ses-
sion. Fifteen 16 mm contiguous axial slices from each arm
were taken from each arm independently. The top of the
bead in a sagittal scout view was used to locate the 8th slice
going from the top of the arm toward the elbow. Scans for
both arms were taken by Fast Spoiled Gradient Recalled
(FSPPGR) and Fast Spin Echo (FSE) with TE 1.8/TR 200
msec. All 8 centers submitted the MRI data to the Research
Center for Genetic Medicine at Children's National Medi-
cal Center (CNMC) in Washington, D.C, via e-mail or
DAT disc, and all scans were integrated into the study SQL
database.
For both cross-sectional and volumetric analysis of the
MRI images, we used Rapidia (INFINITT Inc, Seoul
Korea), a PC based software that allows the semi-auto-
matic quantification of muscle, bone and subcutaneous
fat (figure 1). The software was optimized to provide auto-
mated position adjustment, and to distinguish muscle,
fat, and bone, with automatic edge detection, user modi-
fication of ambiguous edges, and automated propagation
of defined tissue boundaries when possible. Volume
measures were taken using an anatomical landmark (met-BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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aphyseal-diaphyseal junction of the humerus) as our start-
ing point and assayed the six 1 cM slices proximal to it.
Reliability of measures was determined using the
untrained arm, with fat volume measured at a 12 wk inter-
val, showing that our quantitation of subcutaneous fat
was highly reliable and sensitive (R2 = 0.943) (figure 2).
Measurement values were automatically written and
saved in a SQL database together with anthropomorphic
and genotyping data.
Serum biochemistry
Venous blood samples were collected from fasting sub-
jects and serum was separated from blood cells by centrif-
ugation at 1100 × g for 10 min and frozen for further
analysis. Serum samples were analyzed by QuestDiagnos-
tic.
DNA extraction and genotyping
DNA was extracted from blood samples obtained by phle-
botomy before starting the exercise training. Genotyping
was done using the TaqMan allele discrimination assay
that employs the 5' nuclease activity of Taq polymerase to
detect a fluorescent reporter signal generated during PCR
reactions. Oligonucleotide primers used for the L163V
PPARα assay are LVF: CAGAAACAAATGCCAGTATTGTC-
GAT and LVR: CTTACCTACCGTTGTGTGAC ATC. LVV2
VIC: ACAAGTGCCTTTCTG (G allele) and LVM2 AM:
CAAGTGCGTTTCTG (C allele)
Statistical analyses
The Hardy-Weinberg equilibrium was determined for
each SNP using a χ2 test to compare the observed geno-
type frequencies to those expected under H-W equilib-
rium.
Three volumetric measurements were analyzed as contin-
uous quantitative traits (baseline and post-exercise subcu-
taneous fat volumes and difference in subcutaneous fat
volume from baseline to post exercise) for each arm. Nor-
mality of each quantitative trait was confirmed using the
Shapiro-Wilk normality test.
Bivariate correlation analyses of each quantitative meas-
urement showed several significant correlations with age
and baseline mass, therefore, associations between each
SNP and volumetric measurements were assessed using
analysis of covariance (ANCOVA) methods. Due to large
gender differences in baseline values and the response to
training, all analyses were performed separately for men
and women. All significant associations from the main
ANCOVA model were subjected to pair-wise statistical
tests among each of the three genotype groups for each
SNP. Linear tests were performed between each of the gen-
otype groups to determine which genotype groups were
significantly different from one another. The resulting p-
values from these linear tests were adjusted for multiple
comparisons using the Sidak post-hoc multiple compari-
Table 1: Demographic characteristics of Caucasian FAMuSS cohort
Characteristic Females Males
NM e a n  ±  S D NM e a n  ±  S D
Age (years) 378 24.12 ± 7.75 223 26.48 ± 11.70*
Baseline body mass (lbs.) 378 144.35 ± 28.17 223 180.19 ± 37.39 **
Baseline height (in.) 378 64.96 ± 2.63 223 69.94 ± 2.76 **
Baseline BMI 378 24.06 ± 4.66 223 25.88 ± 5.12 **
Post-exercise body mass (lbs.) 378 145.40 ± 28.03 223 181.04 ± 37.15 **
Post-exercise BMI 378 24.22 ± 4.62 223 25.98 ± 5.06 **
Fasting glucose (mg/dL) 378 85.59 ± 7.60 223 90.47 ± 11.67 **
Cholesterol (mg/dL) 359 167.48 ± 32.79 218 168.61 ± 30.70
HDL (mg/dL) 359 52.02 ± 11.60 218 40.95 ± 11.14 **
LDL (mg/dL) 359 96.02 ± 28.61 218 103.75 ± 27.71 ***
Fasting insulin (uIU/mL) 378 5.37 ± 5.26 223 6.09 ± 5.76
Mean BP ^ 372 85.52 ± 8.75 218 90.17 ± 9.21 **
HOMA ^^ 378 1.16 ± 1.49 223 1.40 ± 1.48
Subcutaneous fat volume of the trained arm (mm3) 273 260697 ± 119542 146 181908 ± 97743 **
Subcutaneous fat volume of the untrained arm (mm3) 273 261558 ± 122587 146 184542 ± 105259 **
*p = 0.003
**p < 0.0001
*** p = 0.0015
^Mean BP calculated as (SBP + DBP*2)/3
^^ HOMA calculated as ((Fasting glucose (mg/dL) * 0.0551 * Fasting insulin (uIU/mL))/22.5)BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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son test. Linear regression analysis, including likelihood
ratio tests between full (containing genotype and covari-
ates) and constrained (containing covariates only) mod-
els, were performed to estimate the proportion of variance
in volumetric measurements attributable to each SNP's
genotype.
Results
Genotype association of PPARα L162V polymorphism with 
lipid concentrations
610 Caucasian subjects were selected for this study, based
upon availability of serum samples for lipid and glucose
determination (n = 578), and/or complete MRI data (n =
526) (Table 1). All subjects were genotyped for the PPARα
L162V polymorphism using automated TaqMan assays.
Genotype distribution was in Hardy-Weinberg equilib-
rium. The allele frequencies of the PPARα L162V showed
the rare Valine allele at 7.5% in Caucasians, with18% of
Caucasians heterozygous for the allele. This is similar to
previous reports in other Caucasian populations.
The PPARα 162 valine allele was associated with signifi-
cantly greater serum triglyceride and lower HDL-chol lev-
els in Caucasian men. Heterozygotes for L162V showed
78% higher triglyceride levels than homozygotes for the
common ancestral allele (n = 578; LL genotype = 116.15
3D determination of fat volume Figure 1
3D determination of fat volume. Rapidia determination of subcutaneous fat volume. Panel A: the pink selected area shows 
the subcutaneous fat of one of the six slices measured in the right arm. The red arrow shows the epypheseal flare (anatomical 
landmark used as the starting point of fat determination). Panel B: Left arm, the pink area shows the subcutaneous fat volume 
for other subject. Panel C and D represent the 3D image of panel A and B.BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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Pearson correlation between baseline and post-training subcutaneous fat in the untrained arm of the entire cohort Figure 2
Pearson correlation between baseline and post-training subcutaneous fat in the untrained arm of the entire 
cohort. The correlation coefficient between baseline and post exercise subcutaneous fat volume in the untrained-arm was R2 
= 0.943 (P = 0.001).BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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± 10.82 mg/dL LV genotype = 207.49 ± 29.49 mg/dL; p =
0.004) (Table 2). As 18% of the population carried the
rare allele, the genotype effect of the SNP for all variation
in triglyceride levels was approximately 3.8%. This was a
larger effect size than previously reported for any genetic
modifier of serum triglyceride levels.
LDL cholesterol levels tended to be higher among carriers
of the V162 allele, although these results did not reach sta-
tistical significance (LL genotype = 96 mg/dL LV genotype
= 98 mg/dL).
Heterozygous men showed 20% lower HDL levels than
homozygotes (LL genotype = 41.77 ± 0.78 mg/dL LV gen-
otype = 34.54 ± 2.13 mg/dL p = 0.001).
No significant association between PPARα genotype and
lipids in women, for any subtype of lipid (Table 2).
Genotype association of PPARα L162V polymorphism with 
insulin resistance
We calculated insulin resistant using homeostatic model
assessment (HOMA-IR), where the product of fasting glu-
cose (mmol/L) and fasting insulin (μU/mL) was divided
by 22.5. No significant differences were seen for insulin
resistance and the 162V polymorphism in our cohort.
Genotype association of PPARα L162V polymorphism with 
baseline subcutaneous fat volume
Fat volume was determined using semi-automated three-
dimensional reconstruction analysis software (Figure 1),
with anatomical location specified by the epiphyseal flare
of the humerus. Fat volume was measured for both upper
arms, before and after a 12 week supervised resistance
training program implemented only on one arm. Reliabil-
ity of measures was determined using the untrained arm,
with fat volume measured at a 12 wk interval, showing
that our quantitation of subcutaneous fat was highly reli-
able and sensitive (R2 = 0.943) (figure 2). We considered
Table 2: Analysis of Serum measurements and PPAR alpha (L162V) in Caucasians
Serum 
Measurement
Group Covariates P-value N; Adjusted mean ± SEM p-value for 
significantly 
different means
% variation explained by 
genotype; LRT p-value
Triglycerides All subjects Age 0.0026 CC (N = 500; 102.92 ± 4.49)*
CG (N = 71; 146.80 ± 11.84)*
GG (N = 7; 114.99 ± 37.98)
*p = 0.0018 2.0%; 0.0025
Females Age 0.0474 CC (N = 307; 94.76 ± 2.59)*
CG (N = 45; 111.11 ± 6.77)*
GG (N = 7; 114.72 ± 17.17)
NONE 1.7%; 0.0458
Males Age 0.0040 CC (N = 193; 116.15 ± 10.82)*
CG (N = 26; 207.49 ± 29.49)*
*p = 0.0040 3.8%; 0.0037
HDL All subjects Age 0.0076 CC (N = 500; 48.13 ± 0.56)
CG (N = 70; 44.67 ± 1.48)*
GG (N = 7; 58.43 ± 4.74)*
*p = 0.0173 1.7%; 0.0073
Females Age NS
Males Age 0.0017 CC (N = 193; 41.77 ± 0.78)*
CG (N = 26; 34.54 ± 2.13)*
*p = 0.0017 4.4%; 0.0015
Cholesterol All subjects Age NS
Females Age NS
Males Age NS
VLDL-TG All subjects Age NS
Females Age 0.0441 CC (N = 307; 18.94 ± 0.52)*
CG (N = 45; 22.29 ± 1.35)*
GG (N = 7; 22.77 ± 3.43)
NONE 1.7%; 0.0426
Males Age NS
LDL All subjects Age NS
Females Age NS
Males Age NS
Fasting glucose All subjects Age NS
Females Age 0.0440 CC (N = 307; 85.78 ± 0.41)
CG (N = 45; 83.65 ± 1.03)
GG (N = 7; 89.71 ± 2.58)
NONE 1.5%;0.0426
Males Age NS
Fasting insulin All subjects Age NS
Females Age NS
Males Age NSBMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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six phenotypes for association with PPARα L162V: abso-
lute fat volume baseline (dominant and non-dominant
arms), absolute fat volume after unilateral strength train-
ing intervention (both dominant, and non-dominant
[trained] arms), and absolute change in fat volume (both
dominant and non-dominant arms). All data were strati-
fied for sex (Table 3).
The PPARα 162 valine allele was associated with signifi-
cantly greater baseline subcutaneous fat volume in Cauca-
sian (Table 3). Four different phenotypes all showed
significant genotype effect for absolute measures of fat
volume (trained, un-trained, entry and exit; Table 3). Male
heterozygotes for L162V showed 24% to 38% higher sub-
cutaneous fat of the arm than homozygotes for the com-
mon ancestral allele (LL genotype = 162,106 mm3; LV
genotype = 256,388 mm3). As 18% of the population car-
ried the rare allele, the genotype effect of the SNP for all
variation in regional baseline subcutaneous fat volume is
men was approximately 2% to 4.2% ; Table 3).
We also examined the association between PPARα and
BMI in Caucasian men (as an independent variable). The
Valine allele was associated with higher BMI in Caucasian
men (P = 0.0031) (LL genotype = 25.10, LV genotype =
27.54) (n = 202).
For women, our analysis did not show any statistically sig-
nificant genotype effect for subcutaneous fat.
Genotype effect on exercise-induced changes in 
subcutaneous fat volume
The PPARα 162 valine was associated with increased fat
volume of the untrained arm in male carriers, while LL
genotypes significantly decreased in fat volume (LL = -
1,707 ± 21 mm3, LV = 17,617 ± 58 mm3; p = 0.002) in
men (figure 3; table 3). This suggests that exercise results
systemic loss of subcutaneous fat in LL males, while the
LV carriers showed a large gain in subcutaneous fat.
As with baseline genotype associations, we found no asso-
ciation in women for change of subcutaneous fat as a
function of exercise.
Discussion
The major goal of this study was to identify the role that
PPARα L162V polymorphism may play in the variability
of serum lipid levels, BMI, subcutaneous fat volume, and
Table 3: Analysis of PPAR alpha (L162V) in larger Caucasian only MRI cohort:
Subcutaneous 
fat measure
Gender SNP N: adjusted 
mean ± SEM
P-value for 
significantly 
different means
Variability 
attributable to 
genotype
Likelihood-ratio 
test p-value *
Full model – with age only adjustment
Trained arm – 
baseline fat volume
Male PPAR alpha 
(L162V)
CC (N = 179; 
167221 ± 6710)*
CG (N = 24; 
207418 ± 18325) *
* p = 0.041 2.0% 0.039
Trained arm – 
post-exercise fat 
volume
Male PPAR alpha 
(L162V)
CC (N = 179; 
170608 ± 6952)*
CG (N = 24; 
214926 ± 18932) *
*p = 0.029 2.3% 0.028
Untrained arm – 
baseline fat volume
Male PPAR alpha 
(L162V)
CC (N = 179; 
169890 ± 7106)*
CG (N = 24; 
224144 ± 19407) *
*p = 0.033 2.2% 0.031
Untrained arm – 
post-exercise fat 
volume
Male PPAR alpha 
(L162V)
CC (N = 179; 
168183 ± 7241)*
CG (N = 24; 
231960 ± 19776) *
*p = 0.003 4.2% 0.003
Untrained arm – 
difference in fat 
volume
Male PPAR alpha 
(L162V)
CC (N = 179; -
1707 ± 2133)*
CG (N = 24; 
17617 ± 5826) *
*p = 0.002 4.6% 0.002
Full model – with age and weight adjustment
Untrained arm – 
difference in fat 
volume
Male PPAR alpha 
(L162V)
CC (N = 179; -
1921 ± 2134)*
CG (N = 24; 
17612 ± 5825) *
*p = 0.002 4.9% 0.001BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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change in fat volume in response to unilateral upper arm
resistance training in 610 young (24 yrs) healthy volun-
teers.
We found the V allele to increase triglycerides by 78% (p
= 0.004), and this single polymorphism accounted for
3.8% of all variation in serum triglycerides in males (p =
0.0037). PPARα L162V has been previously shown to be
associated with cholesterol [19] LDL-chol [16-18], HDL-
chol [18] or triglycerides levels [20,21] depending on the
population studied. However, the majority of these asso-
ciation studies have not been replicated. For example, the
effect of the PPARα L162V polymorphism on lipid pro-
files has been studied in middle age subjects with and
without endo-phenotypes of metabolic syndrome in three
different reports. Vohl et al. [17] reported 10% higher LDL
cholesterol levels in carriers of the V allele in non-diabetic
men (n = 193), but not in a diabetic population of men
and women (n = 120) (p = 0.02). In contrast, Flavell et al.
have found higher levels of LDL cholesterol in carriers of
the V allele in subjects with type 2 diabetes (n = 129) but
not in healthy subjects (n = 2508) [18]. Moreover, Lac-
quemant et al. reported higher cholesterol levels in sub-
jects with metabolic syndrome only in the presence of
concomitant coronary heart disease (CHD) [19]. The dis-
crepancies among these studies may be the result of effect
modifiers in different populations, with disease state,
advanced age, and sex each potentially modulating geno-
type/phenotype associations. Our underlying rationale in
this current study was that analysis of young pre-morbid
normal populations would provide the most sensitive and
specific window into PPARα associations with lipid pro-
files. Consistent with our hypothesis, the association of
PPARα and triglycerides in males in this current study
showed a much larger effect of the V allele than previously
reported in older and less healthy populations, with the
rare V allele nearly doubling circulating triglycerides.
Our data showed that the V allele resulted in a 24–38%
increase in subcutaneous fat, and a 20% increase in BMI
(p = 0.0031) (CC genotype = 25.10 kg/m2, CG genotype
= 29.54 kg/m2) in White males. We also found that the
PPARα polymorphism had a strong effect on change in
subcutaneous fat volume after 12 wks of unilateral resist-
ance training in males. Specifically, males homozygous
for the common L allele showed a decrease in fat volume
following unilateral resistance training, while V allele het-
erozygotes showed an increase in subcutaneous fat (p =
0.002). The effect was on both the trained and untrained
arms, suggesting that the PPARα genotype had a strong
systemic effect on subcutaneous fat metabolism, where
the L allele homozygotes showed a beneficial effect of
exercise on adiposity, while the V allele carriers put on
weight with exercise. To our knowledge, this is the first
demonstration of the effect of PPARα genotype on the
outcome of an intervention.
While PPARα Valine allele showed strong statistical signif-
icance with higher subcutaneous fat and BMI in young
Caucasian men in our study, the two previous reports
showed association of the Valine allele with lower per-
centage of body fat, and lower BMI, in overweight and dia-
betic women [22,23]. A possible explanation for this
apparent discrepancy is as follows. Functional studies on
PPARα L162V have reported a higher transactivation of
the receptor in the presence of the variant allele (162V) in
a ligand dependant way [15]. At low ligand levels, the
activity of 162V receptor was lower than the wild type.
However, at high ligand levels, the activity of the poly-
morphic receptor was higher. Since the activity of the
receptor is in part dictated by the concentration of the
receptor agonists and PPARα is activated by fatty acids
among others, we would expect to see higher activity of
the polymorphic receptor in obesity, metabolic syndrome
and type 2 diabetes (in which the levels of fatty acids are
higher). Levels of endogenous and exogenous ligands
(such as dietary fatty acids) may dictate the final pheno-
type observed in the presence of the polymorphism. Our
data in young pre-morbid subjects on lipid levels, BMI
PPARα L162V is associated with changes in subcutaneous fat  volume in response to exercise in men Figure 3
PPARα L162V is associated with changes in subcuta-
neous fat volume in response to exercise in men. In 
men heterozygote for the V162 exercise training increased 
fat volume of the untrained arm. LL genotypes significantly 
decreased in fat volume. No significant differences were seen 
for women. Aged adjusted model.BMC Medical Genetics 2007, 8:55 http://www.biomedcentral.com/1471-2350/8/55
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and subcutaneous fat volume is consistent with the 162V
allele showing lower PPARα activity.
One finding of our study is that women do not show the
same PPARα L162V associations as do men. It is clear that
gender greatly influences both PPARα expression, and
also use of alternative lipid metabolism pathways, and
that both are highly hormone responsive. Djouadi et al.
[25] reported that in PPARα null mice the pharmacologi-
cal inhibition of fatty acid cellular flux caused massive
hepatic and cardiac lipid accumulation, hypoglycemia
(secondary to reduced gluconeogenesis due to the inhibi-
tion of lipid β oxidation), and death in 100% males but
only 25% females. The pretreatment of males with estro-
gens abolished the difference between the two sexes. In
other studies, Jalouli et al. [26] found higher PPARα
mRNA and protein levels in male rats than in female rats.
Gonadectomy of male rats reduced the expression of
PPARα to similar levels as intact female rats. This sug-
gested that not only estrogens may have a role in the reg-
ulation of lipid metabolism but also androgens may be
involved through the increased expression of PPARα. Tak-
ing these results together, young females with circulating
estrogen levels appear to have alternative lipid metabo-
lism pathways that would serve to mask the effect of the
PPARα polymorphism, as we have found in our young
adult populations.
It is important to note that the relatively rare frequency of
the V allele leads to small group sizes of V carriers. Future
studies using specific interventions on pre-genotyped
groups of V allele carriers will be necessary to more fully
characterize the effect of the PPAR V allele on metabolism
and measures of obesity.
Conclusion
We found statistical support for a well characterized
PPARα polymorphism (L162V) with plasma triglycerides,
HDL, subcutaneous fat volume, and change in fat follow-
ing an exercise intervention in 610 Caucasian young
healthy volunteers. Those Caucasian men carrying the
162V allele have nearly double serum triglyceride levels,
lower HDL levels, greater regional subcutaneous fat vol-
ume, higher BMI, and tend to gain subcutaneous fat vol-
ume with an exercise intervention.
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